SPECIAL NOTICE

We are working on upgrading our websites and despite our best endeavours have experienced census type calamities for almost a week now. Our apologies, we hope to have all problems resolved by Monday August 15th.

SEARCH BY NAME

BROWSE

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH BY CODE

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

IMPRESSION HEALTHCARE LIMITED (IHL)

Former Name ASX

SHARE PRICES

Former (or subsequent) names

 FROMTO
INCANNEX HEALTHCARE LIMITED05/07/2020
IMPRESSION HEALTHCARE LIMITED31/10/201606/07/2020
MOUNT MAGNET SOUTH LIMITED03/12/201531/10/2016
MOUNT MAGNET SOUTH NL03/12/2015

Shareholder links

Our website ranking of IHL: rating 2
(2 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Automic Registry Services Level 5 126 Phillip Street Sydney NSW 2000

Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
Fax :
RegistryWebsite RegistryEmail

Company details

Address: 13 Central Avenue Moorabbin VIC 3189
Tel:  +61 (0) 422 180 317 Fax: 

Date first listed: 23/05/2007
Company Secretary: Glenn Fowles
Sector: Health Care Equipment & Services Industry Group: XMJ
Activities: Marketing and manufacturing of oral and dental health products

name changed to Incannex Healthcare Limited

06/07/2020

The suspension of trading in the securities of Impression Healthcare Limited will be lifted immediately following the release by IHL of an announcement regarding a material supply agreement.

09/08/2019

The company has officially launched its wholly owned novel cannabinoid drug discovery brand Incannex Pharmaceuticals. Incannex has engaged Linnea SA to be their supply partner for base cannabinoid materials for two of its four novel cannabinoid formulations under design - TMJ Disorder and TBI/Concussion. Incannex by Impression's four areas of cannabinoid research and imminent clinical trials include: Obstructive Sleep Apnoea, Traumatic Brain Injury (TBI)/Concussion, Temporomandibular Joint (TMJ) Disorder and Periodontitis (Gum Disease) and Gingivitis. IHL under the Incannex brand has also launched a line of EU GMP-approved pharmaceutical grade CBD Oil products to treat conditions prevoiusly approved for treatment with cannabinoids under Special Access Scheme. These Incannex Oils can be sold under Australia's largest distribution network "“ Cannvalate - on a non-exclusive basis. TGA Special Access Scheme Category B Sales for medicinal cannabis products have increased 229% from 670 approvals in January of 2019 to 2206 approvals in July of 2019.

09/08/2019

The securities of Impression Healthcare Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of IHL, pending the release of an announcement regarding a material supply agreement.

08/08/2019

The suspension of trading in the securities of Impression Healthcare Limited will be lifted immediately, following the release by IHL of an announcement regarding its application to the Federal Court of Australia seeking declaratory relief and ancillary orders relating to prior trading in its securities.

21/05/2019

The company's application was heard at 10.15 am on 20 May 2019. The Federal Court has made the orders, and pursuant to these orders, any person who claims to have suffered substantial injustice or is likely to suffer substantial injustice by the making of the orders has liberty to apply to vary or to discharge the orders within 60 days from the date of this announcement and the reinstatement of the company's securities by the ASX .

21/05/2019

The company has become aware that a number of share and option issues made over the past few years were, in erorr, not accompanied by the issue of a cleansing prospectus. The company has filed an application with the Federal Court of Australia seeking declaratory relief and ancillary orders under the Corporations Act to validate prior trading in shares and options issued under the Prior Securities Issues, and relieve persons who have sold those shares and options without further disclosure from any civil liability they may otherwise have. The application will be heard by the Federal Court at 10.15 am on Monday, 20 May 2019.

16/05/2019

The company has lodged a cleansing prospectus to cleanse all relevant shares and options so that subsequent trading of the company's shares and options is not subject to secondary trading restrictions. The Company is also preparing an application to the Federal Court of Australia seeking declaratory relief and ancillary orders to validate prior trading in shares and options issued under the Prior Securities Issues, and relieve persons who have sold those shares and options without further disclosure from any civil liability they may otherwise have. The Company currently expects to file this application early in the week beginning 13 May 2019.

10/05/2019

The company issues a cleansing prospectus for an offer of up to 10,000 New Shares at an issue price of $0.02 per New Share (together with one free attaching New Option for every one (1) New Share subscribed for and issued) to raise up to $200.

10/05/2019

The securities of Impression Healthcare Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of IHL, pending the release of an announcement regarding its application to the Federal Court of Australia seeking declaratory relief and ancillary orders relating to prior trading in its securities.

08/05/2019

The suspension of trading in the securities of Impression Healthcare Limited will be lifted immediately, following the release of an announcement.

19/09/2018

Impression secures letter of intent and exclusivity agreement with leading US-based cannabinoid biotechnology and pharmaceutical company, AXIM Biotechnologies Incorporated. The LOI considers the opportunity for Impression to license and distribute AXIM's current and future range of cannabinoid-based products for distribution by Impression in Australia and New Zealand, subject to regulatory approval. The relationship represents Impression's commitment to innovation and disruption within the oral health sector, the healthcare sector more broadly, and affords Impression the opportunity to license innovative and exciting cannabinoid products. AXIM is focused on research, development and production of oral health, pharmaceutical, nutraceutical and cosmetic products incorporating cannabinoids and has established a full chain of production, including extraction, purification, conversion and microencapsulation. Impression has engaged reputable Melbourne-based consulting firm, Pharmout specialising in cannabinoids to advise it on regulatory and other matters related to AXIM's products.

19/09/2018

The company has executed a capital raise mandate with Alignment Capital Pty Ltd to raise a total of $2.2m by way of three separate funding initiatives: an entitlement-based Rights Issue by way of prospectus; a post-Rights Issue placement; and $750,000 via a fully subscribed converting loan offer.

19/09/2018

The securities of Impression Healthcare Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of IHL, pending the release of an announcement.

18/09/2018

The securities of Impression Healthcare Limited will be reinstated to quotation immediately, following the release of an announcement by the Company.

27/02/2018

The company has received firm commitments to place 48,453,450 fully paid ordinary shares at $0.025 to raise $1,211,336 before costs. Placement funds will primarily be allocated to marketing and promotional activities to accelerate sales growth as the Company works towards achieving break-even and profitability.

27/02/2018

The securities of Impression Healthcare Limited will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company

26/02/2018

The securities of the Company will be reinstated to Official Quotation from the commencement of trading on Tuesday 22 November 2016, following the Company's compliance with Listing Rule 11.1.3 and Chapters 1 and 2 of the ASX Listing Rules.

21/11/2016

name changed from Mount Magnet South Limited

31/10/2016

ASX Announcements (courtesy of ASX)

 

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...


    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    23/03/2018Alistair Blake35,000$0.033$1,140
    04/12/2017Kelvin Smith90,000$0.021$1,879
    02/06/2017Alistair Blake25,691$0.041$1,048
    24/05/2017Alistair Blake34,466$0.056$1,916
    24/05/2017Kelvin Smith40,000$0.053$2,100

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Troy ValentineNon Exec Chairman13/12/2017
    Joel LathamManaging Director, CEO19/07/2018
    Sud AgarwalNon Exec Director25/07/2019
    Peter WiddowsNon Exec Director01/03/2018

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Alistair BlakeDirector20/10/201625/07/2019
    Matthew WestonManaging Director, CEO01/02/201619/07/2018
    Adam WellischIndependent Director03/04/201708/05/2018
    John WorsfoldDirector20/10/201612/12/2017
    Kelvin SmithDirector20/10/201612/12/2017
    Alec PismirisNon Exec Chairman02/08/201303/04/2017
    David LeavyDirector22/12/201420/10/2016
    Michael FennellDirector22/12/201420/10/2016
    Mark PittNon Exec Director26/10/201022/12/2014
    Patrick FlintNon Exec Director15/04/201122/12/2014
    Colin ChenuNon Exec Director14/09/201025/11/2013
    Phillip ShreeveCFO01/06/201101/10/2013
    Reginald GillardNon Exec Chairman15/04/201102/08/2013
    Matthew ShackletonManaging Director18/04/200810/02/2012

    Date of first appointment, title may have changed.